Advanced search
Start date
Betweenand

Molecular analysis of the mechanisms involved in the regulation of EGF, VEGF, HER2 and of the transcriptional factor Foxo3 expression in uterine sarcoma

Grant number: 12/23652-0
Support type:Regular Research Grants
Duration: May 01, 2013 - April 30, 2015
Field of knowledge:Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
Principal Investigator:Kátia Cândido Carvalho
Grantee:Kátia Cândido Carvalho
Home Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Uterine sarcomas are rare mesodermic tumors that include approximately 3% of all uterine cancers. They show histological diversity and aggressive behavior, with early dissemination and high mortality when compared with epithelial tumors. The prognostic is variable, with five years survival rate ranging between 10% and 50%. Because its diversity and rarity, there is no consensus related to risk factors for poor prognostic and appropriated treatment. In this sense, the knowledge of the gene expression regulation can contribute to a better understanding of these neoplasms and to aid the diagnosis and prognostic of their different histological types. Some studies report the expression of growth factors and their receptors in different histological types of sarcoma and was recently demonstrated an essential role for the transcription factor FOXO3 in the regulation of diverse cellular functions. Here, we will evaluate the molecular mechanisms that may be involved in regulation of the growth factors EGF, VEGF, HER2 and transcription factor FOXO3 expression in different histological types of uterine sarcoma. For this, we will use 100 samples of uterine sarcomas (including leiomyosarcomas, carcinosarcomas, adenosarcomas and endometrial stromal sarcomas) obtained from patients during the period of 2000 to 2010. The protein expression of these markers will be analyzed by immunohistochemistry. The promoter methylation and mutation previously in the literature will be evaluated by DNA sequencing. Gene amplification or deletion will be assessed by Fluorescent in situ hybridization (FISH). miRNA expression will be analyzed by quantitative Real Time PCR (qRT-PCR). All results will be submitted to statistical analyses together with patient's data. (AU)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DE ALMEIDA, BRUNA CRISTINE; DOS ANJOS, LAURA GONZALEZ; UNO, MIYUKI; DA CUNHA, ISABELA WERNECK; SOARES, FERNANDO AUGUSTO; BAIOCCHI, GLAUCO; BARACAT, EDMUND CHADA; CARVALHO, KATIA CANDIDO. Let-7 miRNA's Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma. CELLS, v. 8, n. 11 NOV 2019. Web of Science Citations: 0.
DOS ANJOS, LAURA GONZALEZ; DE ALMEIDA, BRUNA CRISTINE; DE ALMEIDA, THAIS GOMES; LAVORATO ROCHA, ANDRE MOURAO; MAFFAZIOLI, GIOVANA DE NARDO; SOARES, FERNANDO AUGUSTO; DA CUNHA, ISABELA WERNECK; BARACAT, EDMUND CHADA; CARVALHO, KATIA CANDIDO. Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and Carcinosarcoma Prognosis and Treatment?. CANCERS, v. 10, n. 9 SEP 2018. Web of Science Citations: 8.
THAIS GOMES DE ALMEIDA; ISABELA WERNECK DA CUNHA; GUSTAVO A R MACIEL; EDMUND CHADA BARACAT; KÁTIA CANDIDO CARVALHO. Clinical and molecular features of uterine sarcomas. MedicalExpress (São Paulo, online), v. 1, n. 6, p. 291-297, Dez. 2014.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.